Exelixis Shares Fall as FDA Extends Zanzalintinib Review Timeline

Key Facts

1Exelixis shares declined following the FDA's announcement to extend the review period for the drug zanzalintinib.

In a sector highly sensitive to regulatory shifts, Exelixis faced notable selling pressure following a key update on its pipeline. Shares of the company declined after the U.S. Food and Drug Administration (FDA) announced an extension of the review period for zanzalintinib. This delay in the regulatory timeline typically creates uncertainty and weighs on investor sentiment regarding the drug's eventual market entry.

Regulatory delays for primary drug candidates are significant catalysts for biotech firms, often leading to immediate price adjustments. Per market data, EXEL shares closed at $57.43 on September 10, 2026. During that session, the stock reached a high of $58.33 and a low of $57.23, illustrating the trading range prior to the news of the extended review period.

Looking ahead, investors will be watching if the stock can maintain support near its recent low of $57.23 (as of the September 10, 2026 close). With no immediate sector-specific catalysts in the upcoming economic calendar, market attention remains focused on further communications from the FDA or Exelixis regarding the revised approval deadline.